CN102002095A - Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof - Google Patents
Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof Download PDFInfo
- Publication number
- CN102002095A CN102002095A CN 201010177981 CN201010177981A CN102002095A CN 102002095 A CN102002095 A CN 102002095A CN 201010177981 CN201010177981 CN 201010177981 CN 201010177981 A CN201010177981 A CN 201010177981A CN 102002095 A CN102002095 A CN 102002095A
- Authority
- CN
- China
- Prior art keywords
- ser
- ala
- lys
- tyr
- ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a novel efficient hypoglycemic balsam pear MC-JJ0108 polypeptide analogue and a microwave irradiation solid phase synthesis method thereof. Locus 1,3,4,7 or 8 of natural balsam pear polypeptide is modified so as to obtain the MC-JJ0108 polypeptide analogue with longer pharmacological action time; and chemical synthesis is realized efficiently and rapidly by a microwave irradiation solid phase synthesis method. A crude product is subject to high-performance liquid purification and is freeze-dried so as to obtain the MC-JJ0108 polypeptide analogue.
Description
Technical field
The present invention relates to MC-JJ0108 polypeptide analog and microwave thereof and promote solid phase synthesis process.
Background technology
Diabetes are important diseases of current harm humans health, and the whole world has the people of 5%-7% to be subjected to diabetes mellitus approximately at present, is considered to after cardiovascular and cerebrovascular diseases, malignant tumour, cause human wounded or disabled, dead the third-largest killer.
Diabetes are divided into I type and II type, and type i diabetes is a kind of autoimmune disease, and patient's survival needs insulin injection.Type ii diabetes accounts for about 95% of numerous diabetic subject's sums.The reason of type ii diabetes is an islet cells metabolism generation obstacle, hypoinsulinism, perhaps producing insulin resistant, is to be main companion's insulin secretion relative deficiency with the insulin resistant, serves as the metabolic disease that main companion's insulin resistant causes with the insulin secretion relative deficiency perhaps.Hypoinsulinism perhaps produces insulin resistant and all can cause in the blood glucose excessive, and when blood-sugar content surpasses the kidney presentation time, glucose is just transferred in the urine and discharged, thereby produces dextrosuria.
The several drugs of clinical application at present all can not be cured diabetes, mainly is by different mechanism of action, reduces patient's glucose level.The diabetic subject must take medicine throughout one's life, and medicine itself is threatening diabetics's health equally to the toxic side effect of human body.In China, use at present medicine can controlling blood sugar to reach arm's length standard, 20% (the Zou Dajin that is less than diabetic subject's sum, the chief culprit of diabetes B---insulin resistant, Popular Medicine, 2002, (6): 17), directly caused many diabetic subjects' complication to take place early, progress is fast.Obviously, except screening more safely and effectively the newtype drug, seeking other the effective glucose level control of auxiliary treatment means, is crucial for the health level that improves the diabetics equally.
Balsam pear (Momordica charantia) is that a kind of mankind have the edible historical vegetables of long-term safety.Recent two decades comes, people have found many compositions with hypoglycemic activity in the fruit of balsam pear, polypeptide composition wherein obtains people's understanding gradually and obtains some utilizations, but because the extraction separation of bitter gourd polypeptide is too complicated, cost is higher to be difficult to obtain pure polypeptide again, and we use modern peptide synthesis technology to address this problem now.
Polypeptide can obtain by the method for engineered method or chemosynthesis.Engineered method has superiority than chemical process obtaining on long peptide (amino-acid residue length is greater than 50) or the protein, but the chemical synthesis process of polypeptide is especially after the solid phase synthesis strategy occurs, handiness, diversity and the high efficiency etc. that have gene engineering method to hardly match on less than 40 polypeptide or little peptide in preparation amino-acid residue length.Merrifield in 1963 found and have developed the method for solid-phase synthetic peptide.Solid-phase polypeptide is synthetic generally two kinds of strategies: i.e. Boc/Bzl orthogonally protect solid phase synthesis strategy and Fmoc/tBu orthogonally protect solid phase synthesis strategy, the solid-phase synthesis that Merrifield foundes is Boc/Bzl orthogonally protect solid phase synthesis strategy.But, have some shortcomings in the Boc/Bzl orthogonally protect solid phase synthesis strategy, many as side reaction, condition is harsh and in the process of prolongation peptide chain polypeptide chain can lose from solid phase etc.The Fmoc/tBu orthogonally protect solid phase synthesis strategy of Chu Xianing reaction conditions gentleness many then subsequently.After microwave technology applies in the solid phase synthesis of polypeptide in recent years, make the synthetic technology of polypeptide produce a leap.Microwave promotes chemical reaction to be because it makes polar molecule fast rotational in microwave field, makes fast 10 to 1000 times of the more conventional heating means of some speed of reaction, and productive rate improves greatly.People's reported first such as Gedye in 1986 with microwave application in organic synthesis, microwave can promote many chemical reactions, as the Diels-Alder reaction, saponification reaction etc. can be accelerated speed of reaction significantly and improve yield.In 1992, Hui-ming Yu etc. reported at first with microwave application that in polypeptide solid phase synthesis field they have finished the synthetic of acyl carrier protein segment decapeptide (acyl carrier protein, ACP 65～74).
How synthetic efficiently long peptide (greater than 20 peptides) remain a challenge in the world, because polypeptide is along with the increase of peptide chain, its synthetic difficulty is multiplied.With the synthetic long peptide of traditional solid phase method, the more purification difficult of the often very low impurity of its yield, thereby say from practical angle and to have lost the synthetic meaning.Secondly synthesis cycle is long, and 30 peptides nearly time in a week of general needs just can not finished synthesis cycle under the centre does not encounter difficulties the situation of peptide preface, if difficult peptide preface, often just can't synthesize and obtains target polypeptides.And use microwave to promote solid-phase synthetic peptide, can overcome difficulties the peptide preface, the polypeptide that synthetic traditional solid phase method can't obtain, and generated time shortens greatly, and significantly improve polypeptide crude product purity and yield, make that the purifying of product is convenient greatly, as long as just can obtain the purity high product through a preparation HPLC; Can carry out pointed decoration with D type amino acid and alpha-non-natural amino acid etc. to polypeptide very easily in addition, remove to seek active higher, polypeptide that biological half-life is longer, this especially genetic engineering technique can't accomplish.Therefore, our employing this kind method synthetic MC-JJ0108 serial analogs that obtains rapidly and efficiently in balsam pear hypoglycemic (MC-JJ0108) polypeptide analog synthetic.
Polypeptide can obtain by the method for engineered method or chemosynthesis.Engineered method has superiority than chemical process obtaining on long peptide (amino-acid residue length is greater than 50) or the protein, but the chemical synthesis process of polypeptide is especially after the solid phase synthesis strategy occurs, handiness, diversity and the high efficiency etc. that have gene engineering method to hardly match on less than 40 polypeptide or little peptide in preparation amino-acid residue length.Merrifield in 1963 found and have developed the method for solid-phase synthetic peptide.Solid-phase polypeptide is synthetic generally two kinds of strategies: i.e. Boc/Bzl orthogonally protect solid phase synthesis strategy and Fmoc/tBu orthogonally protect solid phase synthesis strategy, the solid-phase synthesis that Merrifield foundes is Boc/Bzl orthogonally protect solid phase synthesis strategy.But, have some shortcomings in the Boc/Bzl orthogonally protect solid phase synthesis strategy, many as side reaction, condition is harsh and in the process of prolongation peptide chain polypeptide chain can lose from solid phase etc.The Fmoc/tBu orthogonally protect solid phase synthesis strategy of Chu Xianing reaction conditions gentleness many then subsequently.After microwave technology applies in the solid phase synthesis of polypeptide in recent years, make the synthetic technology of polypeptide produce a leap.Microwave promotes chemical reaction to be because it makes polar molecule fast rotational in microwave field, makes fast 10 to 1000 times of the more conventional heating means of some speed of reaction, and productive rate improves greatly.People's reported first such as Gedye in 1986 with microwave application in organic synthesis, microwave can promote many chemical reactions, as the Diels-Alder reaction, saponification reaction etc. can be accelerated speed of reaction significantly and improve yield.In 1992, Hui-ming Yu etc. reported at first with microwave application that in polypeptide solid phase synthesis field they have finished the synthetic of acyl carrier protein segment decapeptide (acyl carrier protein, ACP 65～74).
How synthetic efficiently long peptide (greater than 30 peptides) remain a challenge in the world, because polypeptide is along with the increase of peptide chain, its synthetic difficulty is multiplied.With the synthetic long peptide of traditional solid phase method, the more purification difficult of the often very low impurity of its yield, thereby say from practical angle and to have lost the synthetic meaning.Secondly synthesis cycle is long, and 30 peptides nearly time in a week of general needs just can not finished synthesis cycle under the centre does not encounter difficulties the situation of peptide preface, if difficult peptide preface, often just can't synthesize and obtains target polypeptides.And use microwave to promote solid-phase synthetic peptide, can overcome difficulties the peptide preface, the polypeptide that synthetic traditional solid phase method can't obtain, and generated time shortens greatly, and significantly improve polypeptide crude product purity and yield, make that the purifying of product is convenient greatly, as long as just can obtain the purity high product through a preparation HPLC; Can carry out pointed decoration with D type amino acid and alpha-non-natural amino acid etc. to polypeptide very easily in addition, remove to seek active higher, polypeptide that biological half-life is longer, this especially genetic engineering technique can't accomplish.Therefore, our employing this kind method synthetic MC-JJ0108 serial analogs that obtains rapidly and efficiently in balsam pear hypoglycemic (MC-JJ0108) polypeptide analog synthetic.
Summary of the invention
The present invention has two first mothers of purpose is to obtain polypeptide to modify and obtain the higher MC-JJ0108 polypeptide analog of hypoglycemic activity from the medicinal and edible plant balsam pear of tool hypoglycemic activity.
Second purpose of the present invention provided the method for preparing solid phase of MC-JJ0108 derivative, and the present invention adopts microwave to promote Fmoc/tBu orthogonally protect solid phase synthesis strategy efficiently to synthesize apace and obtains serial MC-JJ0108 analogue.
It is characterized in that: adopt microwave to promote Fmoc/tBu orthogonally protect solid phase synthesis strategy, earlier syntheticly on solid phase carrier obtain being loaded with first Fmoc and protect amino acid whose resin, ninhydrin method detects sloughs the resin that the Fmoc protecting group obtains being loaded with first amino-acid residue after negative; Enter next coupling circulation again; repeat the step of coupling and deprotection with different protection amino acid according to corresponding peptide preface; prolong required aminoacid sequence successively, the synthetic resin that obtains being loaded with corresponding polypeptide cuts down polypeptide with cracking agent at last and obtains the polypeptide crude product from resin.Crude product is through the preparation scale high-efficient liquid phase chromatogram purification, and freeze-drying gets the pure product of polypeptide.
Be loaded with the preparation method that first Fmoc protects amino acid whose resin; it is characterized in that by obtaining with the solid phase carrier coupling again after the activated dose of activation earlier of Fmoc protection amino acid under the microwave irradiation condition; add 1-hydroxyl-benzotriazole (HOBT) or derivatives thereof in the reaction and suppress racemization, and use the acidity of organic bases neutralization reaction.Being loaded with first Fmoc, to protect the employed solid phase carrier of amino acid whose resin be Rink resin, Wang resin or 2-chlorine trityl chloride resin.Activator is dicyclohexylcarbodiimide (DCC), N, N '-DIC (DIC), N, N " carbonyl dimidazoles (CDI); 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl); 2-(7-azo benzotriazole)-N; N; N '; N '-tetramethyl-urea phosphofluoric acid ester (HATU), benzotriazole-N, N, N ', N '-tetramethyl-urea phosphofluoric acid ester (HBTU) or 1-hydroxyl-benzotriazole (HOBT) derivative that uses are N-hydroxy-succinamide (HOSU), 1-hydroxyl-7-azo benzotriazole (HOAT) or 3-hydroxyl-1,2,3-phentriazine-4 (3H)-ketone (HOOBT).Organic bases is triethylamine (TEA), N-methylmorpholine (NMM) or diisopropylethylamine (DIEA); Microwave promotion condition is: microwave frequency 2450MHz, temperature of reaction: 20～100 ℃, the reaction times is 5～15min.
Removing of Fmoc protecting group is to contain 0.1mol.L by use
-1Hexahydropyridine solution reaction under microwave promotes of 1-hydroxyl-benzotriazole (HOBT), selecting dimethyl formamide (DM F), methyl-sulphoxide (DMSO) or N-Methyl pyrrolidone (NMP) for use is reaction solvent.Microwave promotion condition is: microwave frequency 2450MHz, temperature of reaction: 20～100 ℃, the reaction times is 1～10min.
The invention has the advantages that:
1. a kind of MC-JJ0108 analogue of Ti Chuing can improve the stability of MC-JJ0108 on the basis that keeps hypoglycemic activity, prolongs action time.
2. microwave promotes solid phase synthesis MC-JJ0108 analogue to improve coupled reaction speed greatly, and amino acid of the abundant coupling of conventional solid phase synthesis process goes to resin, often needs do not wait by 20 hours in 2 hours, even longer.Microwave promotes then average to need about 10 minutes; Conventional solid phase synthesis process takes off the Fmoc protecting group, often needs do not wait by 1 hour in 30 minutes, and microwave promotes then on average only to need about 5 minutes, and this has improved polypeptide synthetic efficient greatly, has shortened synthesis cycle.
3. microwave promotes the purity of the synthetic crude product that obtains of solid phase synthesis MC-JJ0108 analogue greater than 80%, more conventional solid phase synthesis process improves greatly, this has made things convenient for follow-up purifying work, only need be through once preparing the liquid phase purifying, and freeze-drying can obtain the pure product of target.
4. microwave promotes the synthetic MC-JJ0108 analogue of solid phase method, and its cost is low because coupling efficiency is higher, required protection amino acid is average only need 2 times excessive, more conventional solid phase synthesis process needs 4 to 5 times excessively greatly to reduce.
5. microwave promotes solid phase synthesis MC-JJ0108 analogue method easily to be automated, to change on a large scale, and this makes it be more suitable for suitability for industrialized production.
Therefore promote the MC-JJ0108 analogue that solid phase synthesis technique prepares with microwave provided by the invention, the yield height, synthesis cycle is short, purifying crude is easy, and production cost is low, be easy to industrial automation production.The MC-JJ0108 analogue for preparing, more stable than natural MC-JJ0108, be suitable as the activeconstituents for the treatment of diabetes medicament.
Embodiment
Adopt following abbreviation in this specification:
Et
3N: triethylamine; The NMM:N-methylmorpholine; DIEA:N, N '-diisopropylethylamine; DMF: dimethyl formamide; DM SO: methyl-sulphoxide; DCM: methylene dichloride; The Fmoc:N-9 fluorenylmethyloxycarbonyl; DIC:N, N '-DIC; CDI:N, N '-carbonyl dimidazoles; The DMAP:4-Dimethylamino pyridine; The HOSU:N-N-Hydroxysuccinimide; EDC.HCl:1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; HATU:2-(7-azo benzotriazole)-N, N, N ', N '-tetramethyl-urea phosphofluoric acid ester; HBTU: benzotriazole-N, N, N ', N '-tetramethyl-urea phosphofluoric acid ester; HCTU:6-chlorobenzene and triazole-1,1,3,3-tetramethyl-urea phosphofluoric acid ester; HOAT:1-hydroxyl-7-azo benzotriazole; HOBT:1-hydroxyl-benzotriazole; PyBOP: phosphofluoric acid benzotriazole-1-base-oxygen base tripyrrole alkyl phosphorus; HPLC: high performance liquid chromatography; ESI-MS: electrospray ionization mass spectrum; Gly: glycine; Ser: Serine; Ala: L-Ala; Thr: Threonine; Val: Xie Ansuan; Ile: Isoleucine; Leu: leucine; Tyr: tyrosine; Phe: phenylalanine; His: Histidine; Pro: proline(Pro); Asp: aspartic acid; Met: methionine(Met); Glu: L-glutamic acid; Trp: tryptophane; Lys: Methionin; Arg: arginine.Asn: l-asparagine; Gln: glutamine.
The present invention describes by following implementation column, but these embodiment do not do any restriction explanation of the present invention.
Embodiment 1
The microwave of Ala-Pro-Ala-Ala-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:2) promotes solid phase synthesis
(1) swelling of resin
Take by weighing Fmoc-rink amide-MBHA Resin 50mg (replacement amount 0.4mmol/g), through 7mL DCM swelling 30min, suction filtration removes DCM, uses 10mL NMP swelling 30min again, uses NMP at last respectively, DCM, and NMP 7mL rinses well.
(2) microwave promotes removing of Fmoc protecting group
The resin that swelling is good is put into reactor, adds 25% piperidines/NMP (V/V) solution that 7mL contains 0.1M HOBT, reacts 1min in microwave reactor, microwave power is 15W, temperature of reaction is controlled in 50 ℃, uses the cooling of air compressor pressurized air, and reaction finishes back elimination solution; Add 25% piperidines/NMP (V/V) solution that 7mL contains 0.1M HOBT again and react 4min again in microwave reactor, microwave power is 25W, and temperature of reaction is controlled at 50 ℃, uses the cooling of air compressor pressurized air.Reaction finishes back elimination solution, uses the NMP washes clean.Obtain sloughing the resin of the Fmoc protecting group of initial connection.
(3) microwave promotes synthesizing of Fmoc-Ser-rink amide-MBHA Resin
With Fmoc-Ser-OH (0.04mmol), HBTU (0.04mmol), HOBT (0.04mmol) and DIPEA (0.08mmol) are dissolved among the 10mL NMP, in the resin above again this solution being added, in microwave reactor, react 7min, microwave power is 25W, and temperature of reaction is controlled at 50 ℃, uses the cooling of air compressor pressurized air.Reaction finishes back filtering reaction solution, uses DCM and each 7mL washing resin of NMP 3 times.
(4) detection of coupling efficiency
With the coupling efficiency of ninhydrin method or bromjophenol blue method qualitative detection resin, color reaction is negative can to enter next coupling circulation.
Ninhydrin method: the resin particle washing with alcohol takes a morsel, put into transparent bottle and add respectively 2 of 5% triketohydrindene hydrate ethanol, KCN pyridine solution (2ml 0.001MKCN is diluted in the 98ml pyridine), 80% phenol ethanolic solns, in 100 ℃ of heating 5 minutes, promptly positive if resin shows blueness.
The bromjophenol blue method: the resin particle that takes a morsel washs with two formyl ethanamides, puts into the tetrabromophenol sulfonphthalein dimethylacetamide solution that transparent bottle adds 3 1%, and jolting is 3 minutes under the normal temperature, and is promptly positive if resin shows blueness.
(5) prolongation of peptide chain
According to Ala
1-MC-JJ0108-(1～21)-NH
2Sequence, the steps in sequence that repeats above-mentioned deprotection and coupling is connected corresponding amino acid, the coupling microwave promotes reaction times 5～20min not wait.Obtain being connected with Ala
1-MC-JJ0108-(1～21)-NH
2Resin.
(6) cracking of polypeptide on the resin
With above-mentioned obtain be connected with Ala
1-MC-JJ0108-(1～21)-NH
2Resin put into reaction flask, each adds cracking agent Reagent K, and (TFA/ thioanisole/water/phenol/EDT, 82.5: 5: 5: 5: 2.5, V/V) 10mL earlier at 0 ℃ of following jolting 30min, reacted 3h more at normal temperatures.Reaction finishes the back suction filtration, adds a small amount of TFA and DCM washing three times, merging filtrate.Filtrate added in a large amount of ice ether separate out white flocks, frozen centrifugation obtains the crude product of target polypeptides.Finally obtain Ala
1-MC-JJ0108-(1～21)-NH
2Crude product 63.2mg, yield are 94.3%.
(7) Ala
1-MC-JJ0108-(1～21)-NH
2The purifying of crude product
With Ala1-MC-JJ0108-(1～the 21)-NH that obtains above
2Crude product is dissolved in a spot of water, prepares type reversed-phase HPLC purifying crude product with Tianjin, island.Adopt the anti-phase preparative column of C18 (340mm * 28mm, 5 μ m) in the purifying; Mobile phase A: 0.1%TFA/ water (V/V), Mobile phase B: 0.1%TFA/ acetonitrile (V/V); Eluent gradient: Mobile phase B 20%～65%, 40min; Flow velocity is 6mL/min; The detection wavelength is 214nm.The solution freeze-drying of collecting gets pure product, finally obtains pure product 29.7mg.Theoretical relative molecular mass 814.9ESI-MSm/z:found[M+3H]
3+272.5, [M+4H]
4+204.8, [M+5H]
5+164.2; Calu[M+3H]
3+272.6, [M+4H]
4+204.7, [M+5H]
5+164.0
According to embodiment 1 described method, according to the synthetic polypeptide that obtains embodiment 2～59 of corresponding sequence, by electrospray ionization mass spectrum (ESI-MS) conclusive evidence molecular weight separately.
Embodiment 2
Ala-Pro-Ala-Cys-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:3); Theoretical relative molecular mass 847.0
ESI-MSm/z：found[M+3H]
3+283.4，[M+4H]
4+212.7，[M+5H]
5+170.3；calu[M+3H]
3+283.3，[M+4H]
4+212.7，[M+5H]
5+170.4
Embodiment 3
Ala-Pro-Ala-Gly-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:4); Theoretical relative molecular mass 800.9
ESI-MSm/z：found[M+3H]
3+268.1，[M+4H]
4+201.1，[M+5H]
5+161.2；calu[M+3H]
3+268.0，[M+4H]
4+201.2，[M+5H]
5+161.2
Embodiment 4
Ala-Pro-Ala-His-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:5); Theoretical relative molecular mass 881.0
ESI-MSm/z：found[M+3H]
3+294.7，[M+4H]
4+221.3，[M+5H]
5+177.0；calu[M+3H]
3+294.7，[M+4H]
4+221.2，[M+5H]
5+177.2
Embodiment 5
Ala-Pro-Ala-Lys-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:6); Theoretical relative molecular mass 872.0
ESI-MSm/z：found[M+3H]
3+291.7，[M+4H]
4+219.1，[M+5H]
5+175.5；calu[M+3H]
3+291.7，[M+4H]
4+219.0，[M+5H]
5+175.4
Embodiment 6
Ala-Pro-Ala-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:7); Theoretical relative molecular mass 907.0
ESI-MSm/z：found[M+3H]
3+303.4，[M+4H]
4+227.7，[M+5H]
5+182.5；calu[M+3H]
3+303.3，[M+4H]
4+227.8，[M+5H]
5+182.4
Embodiment 7
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:8); Theoretical relative molecular mass 999.1
ESI-MSm/z：found[M+3H]
3+334.0，[M+4H]
4+250.9，[M+5H]
5+200.8；calu[M+3H]
3+334.0，[M+4H]
4+250.8，[M+5H]
5+200.8
Embodiment 8
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-(D-Ala)-Ser (SEQ.ID NO:9); Theoretical relative molecular mass 999.1
ESI-MSm/z：found[M+3H]
3+334.0，[M+4H]
4+250.9，[M+5H]
5+200.8；calu[M+3H]
3+334.0，[M+4H]
4+250.8，[M+5H]
5+200.8
Embodiment 9
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:10); Theoretical relative molecular mass 985.1
ESI-MSm/z：found[M+3H]
3+329.4，[M+4H]
4+247.5，[M+5H]
5+197.8；calu[M+3H]
3+329.4，[M+4H]
4+247.3，[M+5H]
5+198.0
Embodiment 10
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:11); Theoretical relative molecular mass 1031.2
ESI-MSm/z：found[M+3H]
3+344.7，[M+4H]
4+258.6，[M+5H]
5+207.1；calu[M+3H]
3+344.7，[M+4H]
4+258.8，[M+5H]
5+207.2
Embodiment 11
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:12); Theoretical relative molecular mass 1059.2
ESI-MSm/z：found[M+3H]
3+354.2，[M+4H]
4+265.7，[M+5H]
5+212.9；calu[M+3H]
3+354.1，[M+4H]
4+265.8，[M+5H]
5+212.8
Embodiment 12
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:13); Theoretical relative molecular mass 1015.1
ESI-MSm/z：found[M+3H]
3+339.5，[M+4H]
4+254.7，[M+5H]
5+203.9；calu[M+3H]
3+339.4，[M+4H]
4+254.8，[M+5H]
5+204.0
Embodiment 13
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID NO:14); Theoretical relative molecular mass 1056.2
ESI-MSm/z：found[M+3H]
3+353.2，[M+4H]
4+265.1，[M+5H]
5+212.3；calu[M+3H]
3+353.1，[M+4H]
4+265.1，[M+5H]
5+212.2
Embodiment 14
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:15); Theoretical relative molecular mass 923.0
ESI-MSm/z：found[M+3H]
3+308.8，[M+4H]
4+231.9，[M+5H]
5+185.7；calu[M+3H]
3+308.7，[M+4H]
4+231.8，[M+5H]
5+185.6
Embodiment 15
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:16); Theoretical relative molecular mass 909.0
ESI-MSm/z：found[M+3H]
3+304.2，[M+4H]
4+228.1，[M+5H]
5+182.7；calu[M+3H]
3+304.0，[M+4H]
4+228.2，[M+5H]
5+182.8
Embodiment 16
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:17); Theoretical relative molecular mass 955.1
ESI-MSm/z：found[M+3H]
3+319.5，[M+4H]
4+239.6，[M+5H]
5+192.0；calu[M+3H]
3+319.4，[M+4H]
4+239.8，[M+5H]
5+192.0
Embodiment 17
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID NO:18); Theoretical relative molecular mass 1008.1
ESI-MSm/z：found[M+3H]
3+337.0，[M+4H]
4+253.1，[M+5H]
5+202.6；calu[M+3H]
3+337.0，[M+4H]
4+253.0，[M+5H]
5+202.6
Embodiment 18
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:19); Theoretical relative molecular mass 983.1
ESI-MSm/z：found[M+3H]
3+328.7，[M+4H]
4+246.8，[M+5H]
5+197.5；calu[M+3H]
3+328.7，[M+4H]
4+246.8，[M+5H]
5+197.6
Embodiment 19
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:20); Theoretical relative molecular mass 939.0
ESI-MSm/z：found[M+3H]
3+314.2，[M+4H]
4+235.8，[M+5H]
5+189.0；calu[M+3H]
3+314.0，[M+4H]
4+235.8，[M+5H]
5+188.8
Embodiment 20
(D-Ala)-Pro-Tyr-Ilr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:21); Theoretical relative molecular mass 985.1
ESI-MSm/z：found[M+3H]
3+329.6，[M+4H]
4+247.2，[M+5H]
5+198.0；calu[M+3H]
3+329.4，[M+4H]
4+247.3，[M+5H]
5+198.0
Embodiment 21
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:22); Theoretical relative molecular mass 1031.2
ESI-MSm/z：found[M+3H]
3+344.9，[M+4H]
4+258.6，[M+5H]
5+207.0；calu[M+3H]
3+344.7，[M+4H]
4+258.8，[M+5H]
5+207.2
Embodiment 22
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:23); Theoretical relative molecular mass 1059.2
ESI-MSm/z：found[M+3H]
3+354.1，[M+4H]
4+265.9，[M+5H]
5+212.7；calu[M+3H]
3+354.1，[M+4H]
4+265.8，[M+5H]
5+212.8
Embodiment 23
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:24); Theoretical relative molecular mass 1015.1
ESI-MSm/z：found[M+3H]
3+339.5，[M+4H]
4+254.8，[M+5H]
5+204.1；calu[M+3H]
3+339.4，[M+4H]
4+254.8，[M+5H]
5+204.0
Embodiment 24
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID NO:25); Theoretical relative molecular mass 1056.2
ESI-MSm/z：found[M+3H]
3+353.3，[M+4H]
4+265.1，[M+5H]
5+212.0；calu[M+3H]
3+353.1，[M+4H]
4+265.1，[M+5H]
5+212.2
Embodiment 25
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:26); Theoretical relative molecular mass 923.0
ESI-MSm/z：found[M+3H]
3+308.8，[M+4H]
4+231.9，[M+5H]
5+185.4；calu[M+3H]
3+308.7，[M+4H]
4+231.8，[M+5H]
5+185.6
Embodiment 26
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:27); Theoretical relative molecular mass 909.0
ESI-MSm/z：found[M+3H]
3+304.0，[M+4H]
4+228.1，[M+5H]
5+182.8；calu[M+3H]
3+304.0，[M+4H]
4+228.2，[M+5H]
5+182.2
Embodiment 27
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:28); Theoretical relative molecular mass 955.1
ESI-MSm/z：found[M+3H]
3+319.3，[M+4H]
4+239.8，[M+5H]
5+192.0；calu[M+3H]
3+319.4，[M+4H]
4+239.8，[M+5H]
5+192.0
Embodiment 28
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID NO:29); Theoretical relative molecular mass 1008.1
ESI-MSm/z：found[M+3H]
3+337.2，[M+4H]
4+253.0，[M+5H]
5+202.7；calu[M+3H]
3+337.0，[M+4H]
4+253.0，[M+5H]
5+202.6
Embodiment 29
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:30); Theoretical relative molecular mass 983.1
ESI-MSm/z：found[M+3H]
3+328.6，[M+4H]
4+246.9，[M+5H]
5+197.6；calu[M+3H]
3+328.7，[M+4H]
4+246.8，[M+5H]
5+197.6
Embodiment 30
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:31); Theoretical relative molecular mass 939.0
ESI-MSm/z：found[M+3H]
3+314.0，[M+4H]
4+235.9，[M+5H]
5+188.8；calu[M+3H]
3+314.0，[M+4H]
4+235.8，[M+5H]
5+188.8
Embodiment 31
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:32); Theoretical relative molecular mass 971.1
ESI-MSm/z：found[M+3H]
3+324.7，[M+4H]
4+243.9，[M+5H]
5+195.3；calu[M+3H]
3+324.7，[M+4H]
4+243.8，[M+5H]
5+195.2
Embodiment 32
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:33); Theoretical relative molecular mass 1017.2
ESI-MSm/z：found[M+3H]
3+340.1，[M+4H]
4+255.2，[M+5H]
5+204.5；calu[M+3H]
3+340.1，[M+4H]
4+255.3，[M+5H]
5+204.4
Embodiment 33
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:34); Theoretical relative molecular mass 1045.2
ESI-MSm/z：found[M+3H]
3+349.4，[M+4H]
4+262.2，[M+5H]
5+210.1；calu[M+3H]
3+349.4，[M+4H]
4+262.3，[M+5H]
5+210.0
Embodiment 34
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:35); Theoretical relative molecular mass 1001.1
ESI-MSm/z：found[M+3H]
3+334.7，[M+4H]
4+251.3，[M+5H]
5+201.4；calu[M+3H]
3+334.7，[M+4H]
4+251.3，[M+5H]
5+201.2
Embodiment 35
Gly-Pro-Tyr-Ilr-Ile-Ser-Lys-Lys-Ser (SEQ.ID NO:36); Theoretical relative molecular mass 1042.2
ESI-MSm/z：found[M+3H]
3+348.3，[M+4H]
4+261.6，[M+5H]
5+209.4；calu[M+3H]
3+348.4，[M+4H]
4+261.5，[M+5H]
5+209.4
Embodiment 36
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:37); Theoretical relative molecular mass 909.0
ESI-MSm/z：found[M+3H]
3+304.2，[M+4H]
4+228.3，[M+5H]
5+182.8；calu[M+3H]
3+304.0，[M+4H]
4+228.2，[M+5H]
5+182.8
Embodiment 37
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:38); Theoretical relative molecular mass 895.0
ESI-MSm/z：found[M+3H]
3+299.4，[M+4H]
4+224.7，[M+5H]
5+180.1；calu[M+3H]
3+299.3，[M+4H]
4+224.7，[M+5H]
5+180.0
Embodiment 38
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:39); Theoretical relative molecular mass 941.1
ESI-MSm/z：found[M+3H]
3+314.6，[M+4H]
4+236.5，[M+5H]
5+189.1；calu[M+3H]
3+314.7，[M+4H]
4+236.3，[M+5H]
5+189.2
Embodiment 39
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID NO:40); Theoretical relative molecular mass 994.1
ESI-MSm/z：found[M+3H]
3+332.4，[M+4H]
4+249.7，[M+5H]
5+199.9；calu[M+3H]
3+332.4，[M+4H]
4+249.5，[M+5H]
5+199.8
Embodiment 40
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:41); Theoretical relative molecular mass 969.1
ESI-MSm/z：found[M+3H]
3+324.0，[M+4H]
4+243.2，[M+5H]
5+194.7；calu[M+3H]
3+324.0，[M+4H]
4+243.3，[M+5H]
5+194.8
Embodiment 41
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:42); Theoretical relative molecular mass 925.0
ESI-MSm/z：found[M+3H]
3+309.2，[M+4H]
4+232.2，[M+5H]
5+186.1；calu[M+3H]
3+309.3，[M+4H]
4+232.2，[M+5H]
5+186.0
Embodiment 42
Ala-Pro-Ala-(D-Ala)-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:43); Theoretical relative molecular mass 814.9
ESI-MSm/z：found[M+3H]
3+272.8，[M+4H]
4+204.6，[M+5H]
5+164.0；calu[M+3H]
3+272.6，[M+4H]
4+204.7，[M+5H]
5+164.0
Embodiment 43
Ala-Pro-Ala-Arg-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:44); Theoretical relative molecular mass 992.1
ESI-MSm/z：found[M+3H]
3+331.8，[M+4H]
4+249.2，[M+5H]
5+199.4；calu[M+3H]
3+331.7，[M+4H]
4+249.0，[M+5H]
5+199.4
Embodiment 44
Ala-Pro-(D-Ala)-Cys-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:45); Theoretical relative molecular mass 847.0
ESI-MSm/z：found[M+3H]
3+283.4，[M+4H]
4+212.6，[M+5H]
5+170.4；calu[M+3H]
3+283.3，[M+4H]
4+212.7，[M+5H]
5+170.4
Embodiment 45
Ala-Pro-(D-Ala)-Gly-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:46); Theoretical relative molecular mass 800.9
ESI-MSm/z：found[M+3H]
3+268.2，[M+4H]
4+201.0，[M+5H]
5+161.3；calu[M+3H]
3+268.0，[M+4H]
4+201.2，[M+5H]
5+161.2
Embodiment 46
Ala-Pro-(D-Ala)-His-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:47); Theoretical relative molecular mass 881.0
ESI-MSm/z：found[M+3H]
3+294.8，[M+4H]
4+221.3，[M+5H]
5+177.2；calu[M+3H]
3+294.7，[M+4H]
4+221.2，[M+5H]
5+177.2
Embodiment 47
Ala-Pro-(D-Ala)-Lys-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:48); Theoretical relative molecular mass 872.0
ESI-MSm/z：found[M+3H]
3+291.8，[M+4H]
4+219.1，[M+5H]
5+175.4；calu[M+3H]
3+291.7，[M+4H]
4+219.0，[M+5H]
5+175.4
Embodiment 48
Ala-Pro-(D-Ala)-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:49); Theoretical relative molecular mass 907.0
ESI-MSm/z：found[M+3H]
3+303.4，[M+4H]
4+227.9，[M+5H]
5+182.5；calu[M+3H]
3+303.3，[M+4H]
4+227.8，[M+5H]
5+182.4
Embodiment 49
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:50); Theoretical relative molecular mass 879.0
ESI-MSm/z：found[M+3H]
3+294.2，[M+4H]
4+220.8，[M+5H]
5+176.9；calu[M+3H]
3+294.0，[M+4H]
4+220.7，[M+5H]
5+176.8
Embodiment 50
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:51); Theoretical relative molecular mass 925.1
ESI-MSm/z：found[M+3H]
3+309.5，[M+4H]
4+232.4，[M+5H]
5+186.0；calu[M+3H]
3+309.4，[M+4H]
4+232.3，[M+5H]
5+186.0
Embodiment 51
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:52); Theoretical relative molecular mass 953.1
ESI-MSm/z：found[M+3H]
3+318.6，[M+4H]
4+232.4，[M+5H]
5+191.6；calu[M+3H]
3+318.7，[M+4H]
4+239.3，[M+5H]
5+191.6
Embodiment 52
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:53); Theoretical relative molecular mass 909.0
ESI-MSm/z：found[M+3H]
3+304.1，[M+4H]
4+228.4，[M+5H]
5+182.9；calu[M+3H]
3+304.0，[M+4H]
4+228.2，[M+5H]
5+182.8
Embodiment 53
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID NO:54); Theoretical relative molecular mass 950.1
ESI-MSm/z：found[M+3H]
3+317.8，[M+4H]
4+238.4，[M+5H]
5+190.9；calu[M+3H]
3+317.7，[M+4H]
4+238.5，[M+5H]
5+191.0
Embodiment 54
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID NO:55); Theoretical relative molecular mass 893.0
ESI-MSm/z：found[M+3H]
3+298.8，[M+4H]
4+224.3，[M+5H]
5+179.6；calu[M+3H]
3+298.7，[M+4H]
4+224.2，[M+5H]
5+179.6
Embodiment 55
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID NO:56); Theoretical relative molecular mass 879.0
ESI-MSm/z：found[M+3H]
3+294.2，[M+4H]
4+220.7，[M+5H]
5+176.6；calu[M+3H]
3+294.0，[M+4H]
4+220.7，[M+5H]
5+176.8
Embodiment 56
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID NO:57); Theoretical relative molecular mass 941.1
ESI-MSm/z：found[M+3H]
3+314.6，[M+4H]
4+236.4，[M+5H]
5+189.2；calu[M+3H]
3+314.7，[M+4H]
4+236.3，[M+5H]
5+189.2
Embodiment 57
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID NO:58); Theoretical relative molecular mass 994.1
ESI-MSm/z：found[M+3H]
3+332.2，[M+4H]
4+249.6，[M+5H]
5+199.8；calu[M+3H]
3+332.4，[M+4H]
4+249.5，[M+5H]
5+199.8
Embodiment 58
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID NO:59); Theoretical relative molecular mass 969.1
ESI-MSm/z：found[M+3H]
3+324.1，[M+4H]
4+243.3，[M+5H]
5+194.8；calu[M+3H]
3+324.0，[M+4H]
4+243.3，[M+5H]
5+194.8
Embodiment 59
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID NO:60); Theoretical relative molecular mass 925.0
ESI-MSm/z：found[M+3H]
3+309.2，[M+4H]
4+232.3，[M+5H]
5+186.0；calu[M+3H]
3+309.3，[M+4H]
4+232.2，[M+5H]
5+186.0
Embodiment 60
Hypoglycemic activity experiment in MC-JJ0108 and the similar object thereof
Get 10 the week age male mouse of kunming (body weight 18～22g), random packet, 6 every group.Tail vein injection tetraoxypyrimidine administration modeling, dosage is 60mg/kg, after 72 hours, mouse fasting 5～6 hours is surveyed blood sugar and is selected the blood glucose value scope 13～23 mouse random packet, 6 every group.The continuous 10d abdominal injection of mouse behind Cheng Mo MC-JJ0108 polypeptide and analogue thereof.0,30,60,90,120 usefulness blood glucose meter are measured blood glucose value.
As shown in table 1, the hypoglycemic activity of MC-JJ0108 polypeptide and analogue thereof is better than N1,N1-Dimethylbiguanide.
Table 1MC-JJ0108 and the hypoglycemic effect of analogue thereof
| 0min | 30min | 60min | 90min | 120min | |
| Negative blank | 4.60±2.38 | 4.68±2.36 | 4.62±1.94 | 4.46±2.02 | 4.12±1.64 |
| Positive blank | 25.32±1.77 | 22.78±2.26 | 21.68±2.82 | 19.16±1.00 | 17.58±2.08 |
| N1,N1-Dimethylbiguanide | 23.15±11.48 | 20.45±5.97 | 18.03±6.24* | 16.01±3.84* | 14.23±5.77* |
| SEQ.ID?NO：2 | 16.45±3.53 | 14.58±2.36*** | 13.36±5.65*** | 11.47±3.46*** | 9.44±5.69** |
| SEQ.ID?NO：4 | 17.55±3.57 | 16.36±6.13** | 15.36±5.79** | 14.64±8.58** | 13.36±4.53* |
| SEQ.ID?NO：7 | 19.44±11.53 | 17.53±7.46 | 15.47±6.53** | 13.34±4.52*** | 12.43±2.49 |
| SEQ.ID?NO：8 | 21.53±0.45 | 19.37±4.55* | 16.58±5.42** | 13.59±6.83*** | 12.51±7.08 |
| SEQ.ID?NO：9 | 20.55±5.46 | 18.46±1.84* | 17.35±4.17* | 16.18±7.45* | 12.51±5.06 |
| SEQ.ID?NO：11 | 18.81±4.43 | 16.28±4.42** | 16.44±0.67* | 14.42±0.94** | 11.67±4.89** |
| SEQ.ID?NO：13 | 17.45±7.37 | 15.58±4.43** | 14.55±3.67*** | 13.82±2.56** | 10.72±2.79*** |
| SEQ.ID?NO：22 | 20.93±3.78 | 18.55±1.64* | 16.62±3.29* | 14.44±2.57** | 14.28±1.65* |
| SEQ.ID?NO：26 | 22.48±1.66 | 16.47±2.75** | 13.44±4.68*** | 11.83±0.41*** | 8.23±0.67*** |
| SEQ.ID?NO：31 | 17.69±0.48 | 16.38±1.57** | 15.49±2.66* | 14.58±4.57 | 13.66±3.74 |
n＝6，
*P＜0.05，**P＜0.01，***P＜0.001?vs?saline
Sequence table
＜110〉China Medicine University
＜120〉microwave promotes solid phase synthesis balsam pear MC-JJ0108 polypeptide analog and application thereof
<160>91
<210>1
<211>21
<212>PRT
＜213〉artificial sequence
<220>
＜221〉synthetic construct
<222>(1)..(1)
＜223〉the 1st Xaa is Ala, D-Ala, Gly or Ser
<220>
＜221〉synthetic construct
<222>(3)..(3)
＜223〉the 3rd Xaa is Ala, D-Ala, Arg, Cys, Gly, His, Lys, Met, Tyr or Ser
<220>
＜221〉synthetic construct
<222>(4)..(4)
＜223〉the 4th Xaa is Ala, D-Ala, Gly, Lys, Tyr or Ser
<220>
＜221〉synthetic construct
<222>(7)..(7)
＜223〉the 7th Xaa is Lys or Ser
<220>
＜221〉synthetic construct
<222>(8)..(8)
＜223〉the 8th Xaa is Ala, D-Ala, Gly, Cys, Arg, Lys, Met or Ser
<400>1
Xaa1-Pro-Xaa2-Xaa3-Ser-Ile-Xaa4-Xaa5-Ser
1 5
<210>2
<211>10
<212>PRT
＜213〉artificial sequence
<400>2
Ala-Pro-Ala-Ala-Ile-Ser-Lys-Ala-Ser
1 5
<210>3
<211>10
<212>PRT
＜213〉artificial sequence
<400>3
Ala-Pro-Ala-Cys-Ile-Ser-Lys-Ala-Ser
1 5
<210>4
<211>10
<212>PRT
＜213〉artificial sequence
<400>4
Ala-Pro-Ala-Gly-Ile-Ser-Lys-Ala-Ser
1 5
<210>5
<211>10
<212>PRT
＜213〉artificial sequence
<400>5
Ala-Pro-Ala-His-Ile-Ser-Lys-Ala-Ser
1 5
<210>6
<211>10
<212>PRT
＜213〉artificial sequence
<400>6
Ala-Pro-Ala-Lys-Ile-Ser-Lys-Ala-Ser
1 5
<210>7
<211>10
<212>PRT
＜213〉artificial sequence
<400>7
Ala-Pro-Ala-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>8
<211>10
<212>PRT
＜213〉artificial sequence
<400>8
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>9
<211>10
<212>PRT
＜213〉artificial sequence
<400>9
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-(D-Ala)-Ser
1 5
<210>10
<211>10
<212>PRT
＜213〉artificial sequence
<400>10
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>11
<211>10
<212>PRT
＜213〉artificial sequence
<400>11
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>12
<211>10
<212>PRT
＜213〉artificial sequence
<400>12
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>13
<211>10
<212>PRT
＜213〉artificial sequence
<400>13
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>14
<211>10
<212>PRT
＜213〉artificial sequence
<400>14
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser
1 5
<210>15
<211>10
<212>PRT
＜213〉artificial sequence
<400>15
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>16
<211>10
<212>PRT
＜213〉artificial sequence
<400>16
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>17
<211>10
<212>PRT
＜213〉artificial sequence
<400>17
Ala-Pro-Ser-Tyr-Ile-Ser-Ls-Cys-Ser
1 5
<210>18
<211>10
<212>PRT
＜213〉artificial sequence
<400>18
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser
1 5
<210>19
<211>10
<212>PRT
＜213〉artificial sequence
<400>19
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>20
<211>10
<212>PRT
＜213〉artificial sequence
<400>20
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>21
<211>10
<212>PRT
＜213〉artificial sequence
<400>21
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>22
<211>10
<212>PRT
＜213〉artificial sequence
<400>22
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>23
<211>10
<212>PRT
＜213〉artificial sequence
<400>23
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>24
<211>10
<212>PRT
＜213〉artificial sequence
<400>24
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>25
<211>10
<212>PRT
＜213〉artificial sequence
<400>25
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser
1 5
<210>26
<211>10
<212>PRT
＜213〉artificial sequence
<400>26
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>27
<211>10
<212>PRT
＜213〉artificial sequence
<400>27
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>28
<211>10
<212>PRT
＜213〉artificial sequence
<400>28
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>29
<211>10
<212>PRT
＜213〉artificial sequence
<400>29
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser
1 5
<210>30
<211>10
<212>PRT
＜213〉artificial sequence
<400>30
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>31
<211>10
<212>PRT
＜213〉artificial sequence
<400>31
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>32
<211>10
<212>PRT
＜213〉artificial sequence
<400>32
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>33
<211>10
<212>PRT
＜213〉artificial sequence
<400>33
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>34
<211>10
<212>PRT
＜213〉artificial sequence
<400>34
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>35
<211>10
<212>PRT
＜213〉artificial sequence
<400>35
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>36
<211>10
<212>PRT
＜213〉artificial sequence
<400>36
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser
1 5
<210>37
<211>10
<212>PRT
＜213〉artificial sequence
<400>37
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>38
<211>10
<212>PRT
＜213〉artificial sequence
<400>38
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>39
<211>10
<212>PRT
＜213〉artificial sequence
<400>39
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>40
<211>10
<212>PRT
＜213〉artificial sequence
<400>40
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser
1 5
<210>41
<211>10
<212>PRT
＜213〉artificial sequence
<400>41
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser
1 5
<210>42
<211>10
<212>PRT
＜213〉artificial sequence
<400>42
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser
1 5
<210>43
<211>10
<212>PRT
＜213〉artificial sequence
<400>43
Ala-Pro-Ala-(D-Ala)-Ile-Ser-Lys-Ala-Ser
1 5
<210>44
<211>10
<212>PRT
＜213〉artificial sequence
<400>44
Ala-Pro-Ala-Arg-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>45
<211>10
<212>PRT
＜213〉artificial sequence
<400>45
Ala-Pro-(D-Ala)-Cys-Ile-Ser-Lys-Ala-Ser
1 5
<210>46
<211>10
<212>PRT
＜213〉artificial sequence
<400>46
Ala-Pro-(D-Ala)-Gly-Ile-Ser-Lys-Ala-Ser
1 5
<210>47
<211>10
<212>PRT
＜213〉artificial sequence
<400>47
Ala-Pro-(D-Ala)-His-Ile-Ser-Lys-Ala-Ser
1 5
<210>48
<211>10
<212>PRT
＜213〉artificial sequence
<400>48
Ala-Pro-(D-Ala)-Lys-Ile-Ser-Lys-Ala-Ser
1 5
<210>49
<211>10
<212>PRT
＜213〉artificial sequence
<400>49
Ala-Pro-(D-Ala)-Tyr-Ile-Ser-Lys-Ala-Ser
1 5
<210>50
<211>10
<212>PRT
＜213〉artificial sequence
<400>50
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Gly-Ser
1 5
<210>51
<211>10
<212>PRT
＜213〉artificial sequence
<400>51
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Cys-Ser
1 5
<210>52
<211>10
<212>PRT
＜213〉artificial sequence
<400>52
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Met-Ser
1 5
Claims (8)
1. balsam pear MC-JJ0108 polypeptide analog that contains formula I (SEQ.ID NO:1) structure with hypoglycemic activity, the balsam pear MC-JJ0108 polypeptide analog that obtains; It is characterized in that its structure has following form:
Xaa
1-Pro-Xaa
2-Xaa
3-Ser-Ile-Xaa
4-Xaa
5-Ser
(SEQ.ID?NO：1)
Xaa
1: Ala, D-Ala, Gly or Ser
Xaa
2: Ala, D-Ala, Arg, Cys, Gly, His, Lys, Met, Tyr or Ser
Xaa
3: Ala, D-Ala, Gly, Lys, Tyr or Ser
Xaa
4: Lys or Ser
Xaa
5: Ala, D-Ala, Gly, Cys, Arg, Lys, Met or Ser
2. polypeptide according to claim 1 has following sequence:
Ala-Pro-Ala-Ala-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：2)
Ala-Pro-Ala-Cys-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：3)
Ala-Pro-Ala-Gly-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：4)
Ala-Pro-Ala-His-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：5)
Ala-Pro-Ala-Lys-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：6)
Ala-Pro-Ala-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：7)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：8)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-(D-Ala)-Ser (SEQ.ID?NO：9)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：10)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：11)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：12)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：13)
Ala-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID?NO：14)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：15)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：16)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：17)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID?NO：18)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：19)
Ala-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：20)
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：21)
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：22)
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：23)
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：24)
(D-Ala)-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID?NO：25)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：26)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：27)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：28)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID?NO：29)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：30)
(D-Ala)-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：31)
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：32)
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：33)
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：34)
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：35)
Gly-Pro-Tyr-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID?NO：36)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：37)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：38)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：39)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID?NO：40)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：41)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：42)
Ala-Pro-Ala-(D-Ala)-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：43)
Ala-Pro-Ala-Arg-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：44)
Ala-Pro-(D-Ala)-Cys-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：45)
Ala-Pro-(D-Ala)-Gly-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：46)
Ala-Pro-(D-Ala)-His-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：47)
Ala-Pro-(D-Ala)-Lys-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：48)
Ala-Pro-(D-Ala)-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：49)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：50)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：51)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：52)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：53)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Lys-Ser (SEQ.ID?NO：54)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Ala-Ser (SEQ.ID?NO：55)
Gly-Pro-Ala-Tyr-Ile-Ser-Lys-Gly-Ser (SEQ.ID?NO：56)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Cys-Ser (SEQ.ID?NO：57)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Arg-Ser (SEQ.ID?NO：58)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Met-Ser (SEQ.ID?NO：59)
Gly-Pro-Ser-Tyr-Ile-Ser-Lys-Ser-Ser (SEQ.ID?NO：60)
3. a pharmaceutical composition comprises the MC-JJ0108 polypeptide analog described in the claim 1 for the treatment of significant quantity or its pharmacy acceptable salt and pharmaceutically acceptable carrier or thinner.
4. the MC-JJ0108 polypeptide analog described in the claim 1 or its pharmacy acceptable salt and pharmaceutically acceptable carrier or thinner are used for the treatment of utilization in the medicine of diabetes in preparation.
5. the preparation method of the MC-JJ0108 polypeptide analog described in the claim 1, it is characterized in that: adopt microwave to promote Fmoc/tBu orthogonally protect solid phase synthesis strategy, earlier syntheticly on solid phase carrier obtain being loaded with first Fmoc and protect amino acid whose resin, ninhydrin method detects sloughs the resin that the Fmoc protecting group obtains being loaded with first amino-acid residue after negative; Enter next coupling circulation again; repeat the step of coupling and deprotection with different protection amino acid according to corresponding peptide preface; prolong required aminoacid sequence successively, the synthetic resin that obtains being loaded with corresponding polypeptide cuts down polypeptide with cracking agent at last and obtains the polypeptide crude product from resin.Crude product is through the preparation scale high-efficient liquid phase chromatogram purification, and freeze-drying gets the pure product of polypeptide.
6. promote solid phase synthesis MC-JJ0108 polypeptide analog method according to microwave described in the claim 5; it is characterized in that being loaded with the preparation method that first Fmoc protects amino acid whose resin; be by obtaining with the solid phase carrier coupling again after the activated dose of activation earlier of Fmoc protection amino acid under the microwave irradiation condition; add 1-hydroxyl-benzotriazole (HOBT) or derivatives thereof in the reaction and suppress racemization, and use the acidity of organic bases neutralization reaction.
7. according to claim 6ly be loaded with the preparation method that first Fmoc protects amino acid whose resin, it is characterized in that the solid phase carrier that uses is Rink resin, Wang resin or 2-chlorine trityl chloride resin; The activator that uses is dicyclohexylcarbodiimide (DCC), N, N '-DIC (DIC), N, N " carbonyl dimidazoles (CDI), 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl), 2-(7-azo benzotriazole)-N; N; N '; N '-tetramethyl-urea phosphofluoric acid ester (HATU), benzotriazole-N; N; N ', N '-tetramethyl-urea phosphofluoric acid ester (HBTU) or 6-chlorobenzene and triazole-1,1,3,3-tetramethyl-urea phosphofluoric acid ester (HCTU); 1-hydroxyl-benzotriazole (HOBT) derivative that uses is N-hydroxy-succinamide (HOSU), 1-hydroxyl-7-azo benzotriazole (HOAT) or 3-hydroxyl-1,2,3-phentriazine-4 (3H)-ketone (HOOBT); The organic bases that uses is triethylamine (TEA), N-methylmorpholine (NMM) or diisopropylethylamine (DIEA); Microwave promotion condition is: microwave frequency 2450MHz, temperature of reaction: 20～100 ℃, the reaction times is 5～15min.
8. promote solid phase synthesis MC-JJ0108 polypeptide analog synthetic method according to microwave described in the claim 5, it is characterized in that removing of Fmoc protecting group is to contain 0.1mol.L by use
-1Hexahydropyridine solution reaction under microwave promotes of 1-hydroxyl-benzotriazole (HOBT), selecting dimethyl formamide (DM F), methyl-sulphoxide (DM SO) or N-Methyl pyrrolidone (NMP) for use is reaction solvent; Microwave promotion condition is: microwave frequency 2450MHz, temperature of reaction: 20～100 ℃, the reaction times is 1～10min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010177981 CN102002095A (en) | 2010-05-20 | 2010-05-20 | Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010177981 CN102002095A (en) | 2010-05-20 | 2010-05-20 | Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102002095A true CN102002095A (en) | 2011-04-06 |
Family
ID=43809822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010177981 Pending CN102002095A (en) | 2010-05-20 | 2010-05-20 | Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102002095A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368152A (en) * | 2015-10-23 | 2018-08-03 | Cem有限公司 | Improvement in Solid phase peptide synthesis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315964A (en) * | 1999-04-13 | 2001-10-03 | 普什帕康纳 | Protein/polypeptide-K obtained from i(momordica charantia) and process for extraction thereof |
| CN1418889A (en) * | 2002-09-23 | 2003-05-21 | 北海海玉农业开发有限责任公司 | Momordi glucose-reducing polypeptide |
| CN1858223A (en) * | 2005-04-30 | 2006-11-08 | 邹远东 | Process for preparing bitter gourd polypeptide and use |
| CN101544981A (en) * | 2008-01-23 | 2009-09-30 | 上海中医药大学 | Method for preparing bitter melon polypeptide with function of reducing blood sugar bioactivity by gene engineering and application |
-
2010
- 2010-05-20 CN CN 201010177981 patent/CN102002095A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315964A (en) * | 1999-04-13 | 2001-10-03 | 普什帕康纳 | Protein/polypeptide-K obtained from i(momordica charantia) and process for extraction thereof |
| CN1418889A (en) * | 2002-09-23 | 2003-05-21 | 北海海玉农业开发有限责任公司 | Momordi glucose-reducing polypeptide |
| CN1858223A (en) * | 2005-04-30 | 2006-11-08 | 邹远东 | Process for preparing bitter gourd polypeptide and use |
| CN101544981A (en) * | 2008-01-23 | 2009-09-30 | 上海中医药大学 | Method for preparing bitter melon polypeptide with function of reducing blood sugar bioactivity by gene engineering and application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368152A (en) * | 2015-10-23 | 2018-08-03 | Cem有限公司 | Improvement in Solid phase peptide synthesis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018032521A1 (en) | Method for synthesizing liraglutide | |
| CN101255191A (en) | Micro-wave promoted solid-phase synthesis of glucagons-like peptide-1(GLP-1) analogue and uses thereof | |
| CA2846680C (en) | Solid phase synthesis of h[gly2]glp-2 | |
| CN105936647A (en) | Long-acting Exendin-4 analogue and application thereof | |
| CN103087180A (en) | Glucagon-like peptide 1 (GLP-1) analogues with long-acting effect and application thereof | |
| CN101463078B (en) | Exendin-4 derivative and solid phase chemical synthesis thereof | |
| CA2020838C (en) | Hemoregulatory peptides | |
| CN105968186B (en) | Glucagon (Glu) analogue with long-acting effect and application thereof | |
| CN110128526A (en) | Long-actingization Exenatide derivative and its salt and preparation method and purposes | |
| CN103087175A (en) | Novel long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof | |
| CN102558298A (en) | Method for synthesizing tetrapeptide isomers by using solid phase peptide synthesis method and applications of tetrapeptide isomers | |
| CN113429471A (en) | Long-acting GLP-1 polypeptide analogue and preparation method and application thereof | |
| CN103694336B (en) | A kind of solid liquid phase fragment condensation prepares the method for Thymosin alpha 1 | |
| WO2018088962A1 (en) | Preparation and use of ginsentides and ginsentide-like peptides | |
| CN107827973A (en) | A kind of solid phase synthesis process of Liraglutide | |
| CN102002095A (en) | Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof | |
| CN101830969A (en) | Balsam pear hypoglycemic MC-JJ0104 polypeptide analogue by microwave-accelerated solid-phase synthesis and application thereof | |
| CN101691398A (en) | Method for solid phase synthesis of bitter gourd MC-JJ2162 peptide analogs under microwave irradiation and application of bitter gourd MC-JJ2162 peptide analogs | |
| CN101665528A (en) | Method for promoting solid phase synthesis of balsam pear MC-JJ2 polypeptide analogue by microwaves and application thereof | |
| CN109721653B (en) | Glucagon-like peptide-1 fragment analogue and application thereof | |
| CN104987383A (en) | GLP-1 derivate | |
| CN101691394B (en) | Method for solid phase synthesis of bitter gourd MC-JJ6 peptide analogs under microwave irradiation and application of bitter gourd MC-JJ6 peptide analogs | |
| CN101824073A (en) | Micro-assisted solid-phase synthesis of analogue of MC-JJ0103 polypeptide isolated from Momordica charantia and application of the analogue | |
| CN101838309A (en) | Solid-phase synthesis of momordica charantia MC-JJ0102 polypeptide analogue under microwave irradiation and application thereof | |
| CN101824074A (en) | Micro-assisted solid-phase synthesis of analogue of MC-JJ0107 polypeptide isolated from Momordica charantia and application of the analogue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110406 |